ライフサイエンスコーパス: clinical end point

1 0, 24, and 48 h after inoculation and at the clinical end point.

2 ime to PSA progression may also be important clinical end point.

3 spectrum of improvement rather than a binary clinical end point.

4 mechanisms of action-of the treatment on the clinical end point.

5 nd nongenetic variables associated with each clinical end point.

6 28-day all-cause mortality rate the primary clinical end point.

7 s too low to advocate its use as a surrogate clinical end point.

8 associated with patient characteristics and clinical end points.

9 s, as are trials using surrogate rather than clinical end points.

10 erall survival, and correlation of EGFR with clinical end points.

11 e or placebo and followed for up to 8 yr for clinical end points.

12 tracted and analyzed according to predefined clinical end points.

13 he SR group, but no differences in the other clinical end points.

14 point was compared with pharmacokinetic and clinical end points.

15 with acute coronary syndrome were considered clinical end points.

16 impact of PSA decline was performed on these clinical end points.

17 oss treatment groups in any of the 3 primary clinical end points.

18 n treatment with respect to any of the major clinical end points.

19 o acetylcholine, preceded the development of clinical end points.

20 nificantly reduce the incidence of important clinical end points.

21 ndiabetic patients for both angiographic and clinical end points.

22 sures of biologic activity as surrogates for clinical end points.

23 reagents and chromogens; and differences in clinical end points.

24 FS) and overall survival (OS) were secondary clinical end points.

25 inal medications), myocardial perfusion, and clinical end points.

26 der to decipher disrupted biology in the two clinical end points.

27 ized by magnetic resonance imaging (MRI) and clinical end points.

28 points may be used as proxy for more robust clinical end points.

29 nd points followed by negative results using clinical end points.

30 the present study was not powered to assess clinical end points.

31 integration of various biomarker assays and clinical end points.

32 were no differences in any of the secondary clinical end points.

33 often report surrogate outcomes rather than clinical end points.

34 ssion-free survival, and overall survival as clinical end points.

35 f conjugate vaccination in studies examining clinical end points.

36 trial designs with appropriate biologic and clinical end points.

37 ve association was strongest for more severe clinical end points.

38 e trials were not powered for superiority in clinical end points.

39 the study design, setting, participants, and clinical end points.

40 lity or hospitalization and in key secondary clinical end points.

41 coronary intervention improves surrogate and clinical end points.

42 tive effects of oral diabetes agents on hard clinical end points.

43 rt positive findings (67%) than trials using clinical end points (54.1%; P = .02).

44 the ramipril group had a 38% reduced risk of clinical end points (95% CI, 13%-56%), a 36% slower mean

45 ated treatment effect, the importance of any clinical end point achieved, and whether patients in the

46 treatment is associated with lower rates of clinical end points, additional to effects of blood pres

47 Pooled estimates for major clinical end points (all-cause mortality, myocardial inf

48 ectiveness of pressure therapies in reducing clinical end points, although 1 trial supported the bene

49 f treatment effects on both the intermediate clinical end point and OS.

50 ted models were developed for four candidate clinical end points and cost.

51 ot improve infectious complications or other clinical end points and may be harmful as suggested by i

52 of study quality, as well as lack of similar clinical end points and measures of magnitude of benefit

53 ry PCI is not associated with any benefit on clinical end points and might increase the risk of strok

54 This article discusses specific clinical end points and their advantages and disadvantag

55 n target-vessel failure at 9 months (primary clinical end point) and a 50% reduction in binary resten

56 e lack of power to sufficiently examine hard clinical end points, and a potential over-reliance on us

57 Data on use of hormonal contraception, clinical end points, and potential confounders were obta

58 A clinical events committee adjudicated clinical end points, and quantitative angiography was pe

59 ion about patient population, interventions, clinical end points, and study design were extracted, an

60 lowing: intention-to-treat analyses, data on clinical end points, and trials comparing nitrofurazone-

61 randomized comparative trials, and important clinical end points are assessed only after decades of f

62 Although data on clinical end-points are lacking, this is likely to be a

63 Clinical end points assessed during a 3-month follow-up

64 Patients receiving stavudine reached clinical end points at a rate of 26 per 100 person-years

65 appear to be any late effect of tirofiban on clinical end points between day 2 and 6 months.

66 time of repeat angiography from the primary clinical end point by as long as possible.

67 Some of its nonspecificity for clinical end points can be ascribed to cross-reactivity

68 eatment efficacy in randomized trials before clinical end points can be evaluated.

69 All deaths were reviewed by a clinical end-point committee, and the mode of death was

70 flammatory response as well as the composite clinical end point compared with surgical necrosectomy.

71 The prespecified composite clinical end point comprised new-onset sustained tachyar

72 he secondary end point was freedom from hard clinical end points (death, AMI recurrence, or stroke),

73 Of the clinical end points, death could be modeled most accurat

74 on between these genotypes and the following clinical end points: development of premature ovarian fa

75 gs suggest that equal weights in a composite clinical end point do not accurately reflect the prefere

76 Clinical end points evaluated included overall survival,

77 ds of borderline statistical significance in clinical end points favoring dual-chamber pacing were ob

78 Autoimmune diabetes is the clinical end point for a sequential cascade of immunolog

79 II/III trials what are the most appropriate clinical end points for anti-signaling molecules such as

80 nsitive to disease progression are needed as clinical end points for future treatment trials in Starg

81 syncytial virus (RSV) to inform selection of clinical end points for RSV vaccine efficacy trials.

82 l validation of HIV-1 RNA as a predictor for clinical end points has implications for the use of HIV-

83 nd other estrogen-sensitive intermediate and clinical end points has not yet been established.

84 reased mortality rate driven by two distinct clinical end points: histological transformation and ear

85 The VE curve describes how VE against the clinical end point (HZ) varies across participant subgro

86 imus-eluting stents (DP-EES) for a composite clinical end point in a population with minimal exclusio

87 ustule and dermis of samples obtained at the clinical end point in the human model of infection.

88 ificant improvement in the composite primary clinical end point in the RITZ-4 trial.

89 centration was significantly associated with clinical end points in participants with impaired kidney

90 beta-blockade is effective in reducing major clinical end points in patients with and without diabete

91 The beneficial effects of digoxin on common clinical end points in patients with HF were similar, re

92 etween increasing concentrations of cTnI and clinical end points in the total study cohort (adjusted

93 s trial and the significantly higher rate of clinical end points in the zidovudine monotherapy group,

94 The primary clinical end point included cardiovascular death, resusc

95 Secondary clinical end points included a predefined composite end

96 Secondary clinical end points included the durability of operation

97 Clinical end points included the presence of paravalvula

98 he relationships of demographic variables to clinical end points, including perioperative (30-day) ev

99 umab resulted in significant improvements in clinical end points, including physician-assessed and de

100 s plus change in LVEF for predicting 4 major clinical end points, including the trial's primary end p

101 re of tumor clonal dynamics leading to these clinical end points is poorly understood, and previously

102 pression in PBLs was not associated with any clinical end point measured.

103 d to adenosine tended to reach the composite clinical end point more often than those assigned to pla

104 A combined clinical end point occurred equally in all the groups.

105 The composite clinical end point occurred less often after endoscopic

106 Each of the clinical end points occurred between 1.9- and 3.5-fold m

107 te subjects for association with the primary clinical end point of asthma exacerbations and changes i

108 Eighteen patients reached the defined clinical end point of death or listing for urgent heart

109 At 1 year, the primary clinical end point of major cardiac events was 63% in th

110 The primary clinical end point of the study was the occurrence of ma

111 Clinical end points of interest were the success and com

112 ess the relationship of TRA with in-hospital clinical end points of major bleeding, transfusion, and

113 ight the need to further compare imaging and clinical end points of PD progression in long-term studi

114 condary outcome was a composite index of the clinical end points of reduction in GFR of more than 50%

115 are-metal stents; we then analyzed the major clinical end points of the trials.

116 did not differ in terms of the EAST primary clinical end points over 3 years.

117 nrolling 50 patients or fewer, those without clinical end points, papers published in a language othe

118 n arbitrary features, consensus criteria for clinical end points provide consistency across studies t

119 between wine consumption, fatal and nonfatal clinical end points, quality of life, symptoms of depres

120 Clinical end point rates and reductions were similar in

121 At a median 24-months of follow-up, our clinical end point rates were 9% for local/regional recu

122 a protocol, and was assessed by nurses using clinical end points rather than a sedation scale.

123 Although clinical end points remain the definitive measure of the

124 of high-quality care and enacting changes in clinical end points remains unclear.

125 Our aim was to determine whether these clinical end point results are also associated with chan

126 cine radiologist (blinded to correlative and clinical end points) reviewed all equivocal PET/CT and B

127 Although this trial was not designed as a clinical end-point study, patients assigned to zidovudin

128 to assess response in relation to important clinical end points such as fracture.

129 om clinical trials was inconclusive on major clinical end points, such as cardiovascular mortality.

130 dy as well as the effect of acetazolamide on clinical end points, such as duration of mechanical vent

131 in clinical trials; and (4) delineation of a clinical end point that is an accurate measure of the un

132 on-resistant prostate cancer (CRPC) need new clinical end points that are valid surrogates for surviv

133 on of emerging insights from the genome into clinical end points that can affect the practice of canc

134 re derived and correlated with the surrogate clinical end points time to first therapy (TTFT) and tim

135 nfocal microscopy may provide an informative clinical end point to evaluate the efficacy of experimen

136 and women have not been well represented in clinical end point trials of pharmacologic lipid-lowerin

137 Unlike clinical end point trials, in which early clinical respo

138 ntibodies incremental to statins in on-going clinical end point trials.

139 cal outcomes requires confirmation in larger clinical end point trials.

140 Clinical end-point trials will be necessary to determine

141 ing the effects of new therapies on multiple clinical end points using the average Z score enables de

142 e influence of increasing site enrollment on clinical end points varied across geographic regions wit

143 rimary end point, defined as vessel-oriented clinical end point (VOCE) at 2 years, was a composite of

144 ears (P =.006) and a 48% reduced risk of the clinical end points vs the amlodipine group (95% confide

145 trength of their associations with different clinical end points warrants investigation.

146 The frequency of the clinical end point was 24 percent with placebos; 3 perce

147 The primary clinical end point was 90-day dichotomized modified Rank

148 The clinical end point was all-cause mortality.

149 The primary clinical end point was mortality within 6 months after t

150 A strong combined genotype effect on each clinical end point was observed.

151 The primary clinical end point was the earliest occurrence of pulmon

152 The primary clinical end point was the occurrence of major adverse c

153 The primary clinical end point was the occurrence of major adverse c

154 The association of galectin-3 with clinical end points was assessed by Cox proportional haz

155 However, the frequency of clinical end points was similar in the subgroup with the

156 At 2-year follow-up, no differences in clinical end point were observed between groups.

157 procedures and 24% reduction in a composite clinical end point were observed in patients assigned to

158 Clinical end points were AD dementia and any type of dem

159 ORs for the 4 clinical end points were calculated for each trial.

160 ctively), neither the 30-day nor the 6-month clinical end points were different among the three group

161 Seven prespecified aggregate clinical end points were examined on an intention-to-tre

162 The primary clinical end points were incidence, cumulative rupture r

163 The clinical end points were ischemic stroke (fatal or nonfa

164 Data on major clinical end points were limited.

165 Clinical end points were measured with 5000-mg double-bl

166 Clinical end points were recorded at 30 days and six mon

167 Long-term clinical end points were similar between groups 1 and 2.

168 The clinical end points were sinus rhythm (SR), death, strok

169 Secondary clinical end points were the length of hospital stay, th

170 Clinical end points were toxicity and rates of objective

171 Secondary clinical end points were weight, lean body mass, muscle

172 termining the correlation of an intermediate clinical end point with OS and the correlation of treatm